Trial Outcomes & Findings for Incidence and Prevalence of Cancer in People Living With HIV/AIDS at Cancer Centers in Latin America (NCT NCT04089488)
NCT ID: NCT04089488
Last Updated: 2023-09-01
Results Overview
The primary endpoint will be the estimates of site-specific frequency of new diagnosis and existing cases (recurrence and surveillance) presenting with HIV and cancer presenting over 1 year, 9 months (21 months) at the clinical sites.
Recruitment status
COMPLETED
Target enrollment
175 participants
Primary outcome timeframe
Up to 21 months
Results posted on
2023-09-01
Participant Flow
Participant milestones
| Measure |
Observational (Respond to Surveys, Medical Record Review)
Patients respond to surveys and/or undergo medical record review at baseline and at 4 weeks.
Medical Chart Review: Correlative studies
Survey Administration: Respond to surveys
|
|---|---|
|
Overall Study
STARTED
|
175
|
|
Overall Study
COMPLETED
|
175
|
|
Overall Study
NOT COMPLETED
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Incidence and Prevalence of Cancer in People Living With HIV/AIDS at Cancer Centers in Latin America
Baseline characteristics by cohort
| Measure |
Observational (Respond to Surveys, Medical Record Review)
n=175 Participants
Patients respond to surveys and/or undergo medical record review at baseline and at 4 weeks.
Medical Chart Review: Correlative studies
Survey Administration: Respond to surveys
|
|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=5 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
167 Participants
n=5 Participants
|
|
Age, Categorical
>=65 years
|
8 Participants
n=5 Participants
|
|
Age, Continuous
|
39 years
n=5 Participants
|
|
Sex: Female, Male
Female
|
37 Participants
n=5 Participants
|
|
Sex: Female, Male
Male
|
138 Participants
n=5 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
171 Participants
n=5 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
4 Participants
n=5 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Asian
|
13 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Black or African American
|
15 Participants
n=5 Participants
|
|
Race (NIH/OMB)
White
|
47 Participants
n=5 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
100 Participants
n=5 Participants
|
|
Region of Enrollment
Argentina
|
26 participants
n=5 Participants
|
|
Region of Enrollment
Brazil
|
49 participants
n=5 Participants
|
|
Region of Enrollment
Mexico
|
100 participants
n=5 Participants
|
PRIMARY outcome
Timeframe: Up to 21 monthsPopulation: There are five study sites (Complexo Hospitalar; Hospital Fernandez; Hospital Roff0; Instituto Nacional De Cancer Brazil ; and Instituto de Oncologia). Given a study site, new diagnosis and existing cases(recurrence and surveillance) are summarized.
The primary endpoint will be the estimates of site-specific frequency of new diagnosis and existing cases (recurrence and surveillance) presenting with HIV and cancer presenting over 1 year, 9 months (21 months) at the clinical sites.
Outcome measures
| Measure |
Observational (Respond to Surveys, Medical Record Review)
n=175 Participants
Patients respond to surveys and/or undergo medical record review at baseline and at 4 weeks.
Medical Chart Review: Correlative studies
Survey Administration: Respond to surveys
|
|---|---|
|
Estimates of Site-specific Incident Cases and Site-specific Prevalence of Cases Presenting With Human Immunodeficiency Virus (HIV) and Cancer Presenting Over 9 Months at the Clinical Sites
Hospital Fernandez (surveillance)
|
5 Participants
|
|
Estimates of Site-specific Incident Cases and Site-specific Prevalence of Cases Presenting With Human Immunodeficiency Virus (HIV) and Cancer Presenting Over 9 Months at the Clinical Sites
Hospital Roffo (new diagnosis)
|
3 Participants
|
|
Estimates of Site-specific Incident Cases and Site-specific Prevalence of Cases Presenting With Human Immunodeficiency Virus (HIV) and Cancer Presenting Over 9 Months at the Clinical Sites
Instituto de Oncologia (new diagnosis)
|
27 Participants
|
|
Estimates of Site-specific Incident Cases and Site-specific Prevalence of Cases Presenting With Human Immunodeficiency Virus (HIV) and Cancer Presenting Over 9 Months at the Clinical Sites
Complexo Hospitalar Professor Edgard Santos (new diagnosis)
|
13 Participants
|
|
Estimates of Site-specific Incident Cases and Site-specific Prevalence of Cases Presenting With Human Immunodeficiency Virus (HIV) and Cancer Presenting Over 9 Months at the Clinical Sites
Complexo Hospitalar Professor Edgard Santos (recurrence)
|
4 Participants
|
|
Estimates of Site-specific Incident Cases and Site-specific Prevalence of Cases Presenting With Human Immunodeficiency Virus (HIV) and Cancer Presenting Over 9 Months at the Clinical Sites
Complexo Hospitalar Professor Edgard Santos (surveillance)
|
10 Participants
|
|
Estimates of Site-specific Incident Cases and Site-specific Prevalence of Cases Presenting With Human Immunodeficiency Virus (HIV) and Cancer Presenting Over 9 Months at the Clinical Sites
Hospital Fernandez (new diagnosis)
|
10 Participants
|
|
Estimates of Site-specific Incident Cases and Site-specific Prevalence of Cases Presenting With Human Immunodeficiency Virus (HIV) and Cancer Presenting Over 9 Months at the Clinical Sites
Hospital Fernandez (recurrence)
|
2 Participants
|
|
Estimates of Site-specific Incident Cases and Site-specific Prevalence of Cases Presenting With Human Immunodeficiency Virus (HIV) and Cancer Presenting Over 9 Months at the Clinical Sites
Hospital Roffo (recurrence)
|
2 Participants
|
|
Estimates of Site-specific Incident Cases and Site-specific Prevalence of Cases Presenting With Human Immunodeficiency Virus (HIV) and Cancer Presenting Over 9 Months at the Clinical Sites
Hospital Roffo (surveillance)
|
4 Participants
|
|
Estimates of Site-specific Incident Cases and Site-specific Prevalence of Cases Presenting With Human Immunodeficiency Virus (HIV) and Cancer Presenting Over 9 Months at the Clinical Sites
Instituto Nacional De Cancer Brazil (new diagnosis)
|
11 Participants
|
|
Estimates of Site-specific Incident Cases and Site-specific Prevalence of Cases Presenting With Human Immunodeficiency Virus (HIV) and Cancer Presenting Over 9 Months at the Clinical Sites
Instituto Nacional De Cancer Brazil (recurrence)
|
2 Participants
|
|
Estimates of Site-specific Incident Cases and Site-specific Prevalence of Cases Presenting With Human Immunodeficiency Virus (HIV) and Cancer Presenting Over 9 Months at the Clinical Sites
Instituto Nacional De Cancer Brazil (surveillance)
|
9 Participants
|
|
Estimates of Site-specific Incident Cases and Site-specific Prevalence of Cases Presenting With Human Immunodeficiency Virus (HIV) and Cancer Presenting Over 9 Months at the Clinical Sites
Instituto de Oncologia (recurrence)
|
9 Participants
|
|
Estimates of Site-specific Incident Cases and Site-specific Prevalence of Cases Presenting With Human Immunodeficiency Virus (HIV) and Cancer Presenting Over 9 Months at the Clinical Sites
Instituto de Oncologia (surveillance)
|
64 Participants
|
PRIMARY outcome
Timeframe: 21 monthsPopulation: There are five study sites (Complexo Hospitalar; Hospital Fernandez; Hospital Roff0; Instituto Nacional De Cancer Brazil ; and Instituto de Oncologia). Given a study site, new diagnosis cases are summarized using cases per month.
The mean cases per month of incidence will be estimated along with corresponding 95% Poisson confidence interval. The number of cases will be counted and mean cases per months will be estimated. Duration of observation was 21 months. This summary was based on the study site.
Outcome measures
| Measure |
Observational (Respond to Surveys, Medical Record Review)
n=175 Participants
Patients respond to surveys and/or undergo medical record review at baseline and at 4 weeks.
Medical Chart Review: Correlative studies
Survey Administration: Respond to surveys
|
|---|---|
|
Mean Cases Per Month of New Cases Were Estimated Along With Corresponding 95% Poisson Confidence Interval by Study Site.
Complexo Hospitalar Professor Edgard Santos (new diasgnosis)
|
0.62 New diagnosis cases per month
Interval 0.33 to 1.06
|
|
Mean Cases Per Month of New Cases Were Estimated Along With Corresponding 95% Poisson Confidence Interval by Study Site.
Instituto Nacional De Cancer Brazil (new diagnosis)
|
0.52 New diagnosis cases per month
Interval 0.26 to 0.94
|
|
Mean Cases Per Month of New Cases Were Estimated Along With Corresponding 95% Poisson Confidence Interval by Study Site.
Instituto de Oncologia (new diagnosis)
|
1.29 New diagnosis cases per month
Interval 0.84 to 1.87
|
|
Mean Cases Per Month of New Cases Were Estimated Along With Corresponding 95% Poisson Confidence Interval by Study Site.
Hospital Fernandez (new diagnosis)
|
0.48 New diagnosis cases per month
Interval 0.23 to 0.88
|
|
Mean Cases Per Month of New Cases Were Estimated Along With Corresponding 95% Poisson Confidence Interval by Study Site.
Hospital Roffo (new diagnosis)
|
0.14 New diagnosis cases per month
Interval 0.03 to 0.42
|
PRIMARY outcome
Timeframe: 21 monthsPopulation: The numbers of participants per cancer type were displayed.
The mean cases per month of incidence will be estimated along with corresponding 95% Poisson confidence interval. The number of cases will be counted and mean cases per months will be estimated. Duration of observation was 21 months. This summary was based on the cancer type.
Outcome measures
| Measure |
Observational (Respond to Surveys, Medical Record Review)
n=175 Participants
Patients respond to surveys and/or undergo medical record review at baseline and at 4 weeks.
Medical Chart Review: Correlative studies
Survey Administration: Respond to surveys
|
|---|---|
|
Mean Cases Per Month of New Cases Were Estimated Along With Corresponding 95% Poisson Confidence Interval by Cancer Type.
Other (new diagnosis)
|
0.67 Mean cases per month
Interval 0.36 to 1.12
|
|
Mean Cases Per Month of New Cases Were Estimated Along With Corresponding 95% Poisson Confidence Interval by Cancer Type.
Kaposi sarcoma (new diagnosis)
|
1.19 Mean cases per month
Interval 0.77 to 1.75
|
|
Mean Cases Per Month of New Cases Were Estimated Along With Corresponding 95% Poisson Confidence Interval by Cancer Type.
Non-Hodgkin's Lymphoma (new diagnisis)
|
0.86 Mean cases per month
Interval 0.51 to 1.35
|
|
Mean Cases Per Month of New Cases Were Estimated Along With Corresponding 95% Poisson Confidence Interval by Cancer Type.
Hodgkin's lymphoma (new diagnosis)
|
0.24 Mean cases per month
Interval 0.08 to 0.56
|
|
Mean Cases Per Month of New Cases Were Estimated Along With Corresponding 95% Poisson Confidence Interval by Cancer Type.
Anal cancer (new diagnosis)
|
0 Mean cases per month
Interval 0.0 to 0.0
|
|
Mean Cases Per Month of New Cases Were Estimated Along With Corresponding 95% Poisson Confidence Interval by Cancer Type.
Cervical cancer (new diagnosis)
|
0.10 Mean cases per month
Interval 0.01 to 0.34
|
PRIMARY outcome
Timeframe: 21 monthsPopulation: The numbers of participants per study site were displayed.
The mean cases per month of prevalence will be estimated along with corresponding 95% Poisson confidence interval. The number of cases will be counted and mean cases per months will be estimated. Duration of observation was 21 months. This summary was based on the study site.
Outcome measures
| Measure |
Observational (Respond to Surveys, Medical Record Review)
n=175 Participants
Patients respond to surveys and/or undergo medical record review at baseline and at 4 weeks.
Medical Chart Review: Correlative studies
Survey Administration: Respond to surveys
|
|---|---|
|
Mean Cases Per Month of Existing Cases Were Estimated Along With Corresponding 95% Poisson Confidence Interval by Study Site.
Complexo Hospitalar Professor Edgard Santos
|
.67 mean cases per month
Interval 0.36 to 1.12
|
|
Mean Cases Per Month of Existing Cases Were Estimated Along With Corresponding 95% Poisson Confidence Interval by Study Site.
Instituto Nacional De Cancer Brazil
|
0.52 mean cases per month
Interval 0.26 to 0.94
|
|
Mean Cases Per Month of Existing Cases Were Estimated Along With Corresponding 95% Poisson Confidence Interval by Study Site.
Instituto de Oncologia
|
3.48 mean cases per month
Interval 2.72 to 4.37
|
|
Mean Cases Per Month of Existing Cases Were Estimated Along With Corresponding 95% Poisson Confidence Interval by Study Site.
Hospital Fernandez
|
0.33 mean cases per month
Interval 0.13 to 0.69
|
|
Mean Cases Per Month of Existing Cases Were Estimated Along With Corresponding 95% Poisson Confidence Interval by Study Site.
Hospital Roffo
|
0.29 mean cases per month
Interval 0.1 to 0.62
|
PRIMARY outcome
Timeframe: 21 monthsPopulation: The numbers of participants per cancer type were displayed.
The mean cases per month of prevalence will be estimated along with corresponding 95% Poisson confidence interval. The number of cases will be counted and mean cases per months will be estimated. Duration of observation was 21 months. This summary was based on the cancer type.
Outcome measures
| Measure |
Observational (Respond to Surveys, Medical Record Review)
n=175 Participants
Patients respond to surveys and/or undergo medical record review at baseline and at 4 weeks.
Medical Chart Review: Correlative studies
Survey Administration: Respond to surveys
|
|---|---|
|
Mean Cases Per Month of Existing Cases Were Estimated Along With Corresponding 95% Poisson Confidence Interval by Cancer Type
Kaposi sarcoma
|
2.14 Mean cases per month
Interval 1.56 to 2.87
|
|
Mean Cases Per Month of Existing Cases Were Estimated Along With Corresponding 95% Poisson Confidence Interval by Cancer Type
non-Hodgkin's Lymphoma
|
1.33 Mean cases per month
Interval 0.89 to 1.93
|
|
Mean Cases Per Month of Existing Cases Were Estimated Along With Corresponding 95% Poisson Confidence Interval by Cancer Type
Hodgkin's Lymphoma
|
0.38 Mean cases per month
Interval 0.16 to 0.75
|
|
Mean Cases Per Month of Existing Cases Were Estimated Along With Corresponding 95% Poisson Confidence Interval by Cancer Type
Anal cancer
|
0.14 Mean cases per month
Interval 0.03 to 0.42
|
|
Mean Cases Per Month of Existing Cases Were Estimated Along With Corresponding 95% Poisson Confidence Interval by Cancer Type
Cervical cancer
|
0.14 Mean cases per month
Interval 0.03 to 0.42
|
|
Mean Cases Per Month of Existing Cases Were Estimated Along With Corresponding 95% Poisson Confidence Interval by Cancer Type
Other
|
1.14 Mean cases per month
Interval 0.73 to 1.7
|
SECONDARY outcome
Timeframe: Up to 21 monthsThe frequency of diagnostic testing modalities will be summarized for cancer.
Outcome measures
| Measure |
Observational (Respond to Surveys, Medical Record Review)
n=175 Participants
Patients respond to surveys and/or undergo medical record review at baseline and at 4 weeks.
Medical Chart Review: Correlative studies
Survey Administration: Respond to surveys
|
|---|---|
|
Information on the Use of Diagnostic Testing in HIV-positive Individuals
Histology (Other)
|
38 Participants
|
|
Information on the Use of Diagnostic Testing in HIV-positive Individuals
Unknown
|
1 Participants
|
|
Information on the Use of Diagnostic Testing in HIV-positive Individuals
Histology (Kaposi sarcoma)
|
62 Participants
|
|
Information on the Use of Diagnostic Testing in HIV-positive Individuals
Clinical only (Kaposi sarcoma)
|
7 Participants
|
|
Information on the Use of Diagnostic Testing in HIV-positive Individuals
Histology (Non-Hodgkin's lymphoma)
|
45 Participants
|
|
Information on the Use of Diagnostic Testing in HIV-positive Individuals
Cytology (Non-Hodgkin's lymphoma)
|
1 Participants
|
|
Information on the Use of Diagnostic Testing in HIV-positive Individuals
Histology (Hodgkin's lymphoma)
|
12 Participants
|
|
Information on the Use of Diagnostic Testing in HIV-positive Individuals
Cytology (Hodgkin's lymphoma)
|
1 Participants
|
|
Information on the Use of Diagnostic Testing in HIV-positive Individuals
Histology(Anal)
|
3 Participants
|
|
Information on the Use of Diagnostic Testing in HIV-positive Individuals
Histology (Cervical)
|
5 Participants
|
SECONDARY outcome
Timeframe: Up to 21 monthsFor each cancer, summary statistics will be used to describe the HIV treatment regimens and disease characteristics.
Outcome measures
| Measure |
Observational (Respond to Surveys, Medical Record Review)
n=175 Participants
Patients respond to surveys and/or undergo medical record review at baseline and at 4 weeks.
Medical Chart Review: Correlative studies
Survey Administration: Respond to surveys
|
|---|---|
|
HIV Treatment and Disease Characteristics of HIV-positive Individuals Diagnosed With Cancer
Kaposi sarcoma (NNRTI only)
|
17 Participants
|
|
HIV Treatment and Disease Characteristics of HIV-positive Individuals Diagnosed With Cancer
Kaposi sarcoma (Combination)
|
48 Participants
|
|
HIV Treatment and Disease Characteristics of HIV-positive Individuals Diagnosed With Cancer
Kaposi sarcoma (No HIV treatment)
|
5 Participants
|
|
HIV Treatment and Disease Characteristics of HIV-positive Individuals Diagnosed With Cancer
Non-Hodgkin's lymphoma (NNRTI only)
|
18 Participants
|
|
HIV Treatment and Disease Characteristics of HIV-positive Individuals Diagnosed With Cancer
Non-Hodgkin's lymphoma (Combination)
|
25 Participants
|
|
HIV Treatment and Disease Characteristics of HIV-positive Individuals Diagnosed With Cancer
Non-Hodgkin's lymphoma (No HIV treatment)
|
3 Participants
|
|
HIV Treatment and Disease Characteristics of HIV-positive Individuals Diagnosed With Cancer
Hodgkin's lymphoma (NNRTI only)
|
4 Participants
|
|
HIV Treatment and Disease Characteristics of HIV-positive Individuals Diagnosed With Cancer
Hodgkin's lymphoma (Combination)
|
8 Participants
|
|
HIV Treatment and Disease Characteristics of HIV-positive Individuals Diagnosed With Cancer
Hodgkin's lymphoma (No HIV treatment)
|
1 Participants
|
|
HIV Treatment and Disease Characteristics of HIV-positive Individuals Diagnosed With Cancer
Anal (NNRTI only)
|
1 Participants
|
|
HIV Treatment and Disease Characteristics of HIV-positive Individuals Diagnosed With Cancer
Anal (Combination)
|
2 Participants
|
|
HIV Treatment and Disease Characteristics of HIV-positive Individuals Diagnosed With Cancer
Cervical (Combination)
|
4 Participants
|
|
HIV Treatment and Disease Characteristics of HIV-positive Individuals Diagnosed With Cancer
Cervical (No HIV treatment)
|
1 Participants
|
|
HIV Treatment and Disease Characteristics of HIV-positive Individuals Diagnosed With Cancer
Other (NNRTI only)
|
21 Participants
|
|
HIV Treatment and Disease Characteristics of HIV-positive Individuals Diagnosed With Cancer
Other (Combination)
|
12 Participants
|
|
HIV Treatment and Disease Characteristics of HIV-positive Individuals Diagnosed With Cancer
Other (No HIV treatment)
|
5 Participants
|
SECONDARY outcome
Timeframe: Up to 21 monthsThe frequency of the Treatment for Cancers Diagnosed in HIV-positive Individuals will be summarized.
Outcome measures
| Measure |
Observational (Respond to Surveys, Medical Record Review)
n=175 Participants
Patients respond to surveys and/or undergo medical record review at baseline and at 4 weeks.
Medical Chart Review: Correlative studies
Survey Administration: Respond to surveys
|
|---|---|
|
Information on the Treatment for Cancers Diagnosed in HIV-positive Individuals
Surgery only
|
3 Participants
|
|
Information on the Treatment for Cancers Diagnosed in HIV-positive Individuals
surgery and chemotherapy
|
2 Participants
|
|
Information on the Treatment for Cancers Diagnosed in HIV-positive Individuals
Radiation only
|
2 Participants
|
|
Information on the Treatment for Cancers Diagnosed in HIV-positive Individuals
Radiation and chemotherapy
|
3 Participants
|
|
Information on the Treatment for Cancers Diagnosed in HIV-positive Individuals
Chemotherapy only
|
24 Participants
|
|
Information on the Treatment for Cancers Diagnosed in HIV-positive Individuals
Chemotherapy and other
|
1 Participants
|
|
Information on the Treatment for Cancers Diagnosed in HIV-positive Individuals
Other
|
11 Participants
|
|
Information on the Treatment for Cancers Diagnosed in HIV-positive Individuals
No information
|
129 Participants
|
SECONDARY outcome
Timeframe: BaselinePopulation: 1 missing CD4 value
CD4 percent of HIV-positive Individuals Diagnosed With Cancer will be summarized.
Outcome measures
| Measure |
Observational (Respond to Surveys, Medical Record Review)
n=174 Participants
Patients respond to surveys and/or undergo medical record review at baseline and at 4 weeks.
Medical Chart Review: Correlative studies
Survey Administration: Respond to surveys
|
|---|---|
|
CD4 of HIV-positive Individuals Diagnosed With Cancer
Kaposi sarcoma
|
15 Percentage of CD4 cells
Interval 8.0 to 22.0
|
|
CD4 of HIV-positive Individuals Diagnosed With Cancer
Non-Hodgkin's lymphoma
|
14.5 Percentage of CD4 cells
Interval 9.0 to 25.0
|
|
CD4 of HIV-positive Individuals Diagnosed With Cancer
Hodgkin's lymphoma
|
17 Percentage of CD4 cells
Interval 16.0 to 24.0
|
|
CD4 of HIV-positive Individuals Diagnosed With Cancer
Anal
|
18 Percentage of CD4 cells
Interval 13.0 to 24.0
|
|
CD4 of HIV-positive Individuals Diagnosed With Cancer
Cervical
|
18 Percentage of CD4 cells
Interval 16.0 to 24.0
|
|
CD4 of HIV-positive Individuals Diagnosed With Cancer
Other
|
26 Percentage of CD4 cells
Interval 18.0 to 35.0
|
SECONDARY outcome
Timeframe: BaselinePopulation: 89 participants were assessed for this Outcome Measure.
HIV viral load of HIV-positive Individuals Diagnosed With Cancer will be summarized
Outcome measures
| Measure |
Observational (Respond to Surveys, Medical Record Review)
n=89 Participants
Patients respond to surveys and/or undergo medical record review at baseline and at 4 weeks.
Medical Chart Review: Correlative studies
Survey Administration: Respond to surveys
|
|---|---|
|
HIV Viral Load of HIV-positive Individuals Diagnosed With Cancer
Anal
|
30 copies per ml
Interval 20.0 to 40.0
|
|
HIV Viral Load of HIV-positive Individuals Diagnosed With Cancer
Cervical
|
40.5 copies per ml
Interval 40.0 to 41.0
|
|
HIV Viral Load of HIV-positive Individuals Diagnosed With Cancer
Other
|
40 copies per ml
Interval 40.0 to 47.0
|
|
HIV Viral Load of HIV-positive Individuals Diagnosed With Cancer
Kaposi sarcoma
|
46 copies per ml
Interval 40.0 to 1125.0
|
|
HIV Viral Load of HIV-positive Individuals Diagnosed With Cancer
Non-Hodgkin's lymphoma
|
40.5 copies per ml
Interval 40.0 to 29246.0
|
|
HIV Viral Load of HIV-positive Individuals Diagnosed With Cancer
Hodgkin's lymphoma49
|
49 copies per ml
Interval 40.0 to 364.0
|
Adverse Events
Observational (Respond to Surveys, Medical Record Review)
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Deukwoo Kwon
Statistical and Data Analysis Center, AIDS Malignancy Consortium
Phone: (713) 500-7964
Email: [email protected]
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place